Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.